Dr. Usmani on Combining Daratumumab for Multiple Myeloma

Saad Z. Usmani, MD
Published: Thursday, Apr 20, 2017



Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses combining daratumumab (Darzalex) for patients with multiple myeloma.

Depending on the therapy that patients have received for their first-line of treatment, daratumumab may have the ability to be paired with other agents, explains Usmani.

A concern that physicians have is long-term effects of daratumumab on the immune system. As of now, there is no clinically significant concerns but it is something we will continue to watch, states Usmani.
 
SELECTED
LANGUAGE


Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses combining daratumumab (Darzalex) for patients with multiple myeloma.

Depending on the therapy that patients have received for their first-line of treatment, daratumumab may have the ability to be paired with other agents, explains Usmani.

A concern that physicians have is long-term effects of daratumumab on the immune system. As of now, there is no clinically significant concerns but it is something we will continue to watch, states Usmani.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x